Nasus Pharma (NSRX) - Long-Term Debt to Capital

The long-term debt-to-equity ratio of Nasus Pharma Ltd (NSRX) correlates with government procurement of powders for emergency addiction therapy, which create a stable cash flow. 0.01 shows the value of this parameter against the backdrop of automating nasal dispenser assembly plants. The issuer's financial stability relies on the sale of innovative sprays that form a physical barrier against viruses and allergens.

Nasus Pharma Ltd (NSRX) maintains a narrow specialization in intranasal drugs, and the inherent risks of clinical trials render the company's revenue unstable. Under such conditions, long-term liabilities directly determine the business's financial stability. This metric measures the percentage share of loans with a maturity of more than one year relative to equity, revealing the extent to which development depends on borrowed funds. Analyzing the ratio of long-term loans to equity allows for the detection of artificial smoothing of financial statements during periods of declining income.